0B68 Pro, Barbara - Thomas Jefferson University - Thomas Jefferson University
bxp022

Barbara Pro, MD

Contact Dr. Pro

925 Chestnut Street
Suite 420A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study)
  2. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses
  3. Peripheral T-cell lymphomas: A review of current approaches and hopes for the future
  4. Phase i study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
  5. Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo®) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas
  6. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial
  7. Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma
  8. A phase 2 study of epothilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas
  9. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: A prospective, randomized controlled phase III trial
  10. Non-Hodgkin's lymphomas, version 1.2013: Featured updates to the NCCN guidelines
  11. Heads or tails? Choosing a salvage therapy for relapsed/refractory Hodgkin lymphoma
  12. Targeting CD30 in anaplastic large cell lymphoma
  13. Non-Hodgkin's Lymphomas, version 3.2012: Featured updates to the NCCN guidelines
  14. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: Results of an F2-study database
  15. Second-line 90yttrium-ibritumomab tiuxetan (Zevalin) in a patient with conjunctival mucosa-associated lymphoid tissue lymphoma refractory to rituximab
  16. Brentuximab vedotin in Hodgkin's lymphoma
  17. Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: A subgroup efficacy analysis from the PROPEL study
  18. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study
  19. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
  20. Phase 2 study of rituximab plusABVD in patients with newly diagnosed classical Hodgkin lymphoma
0